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Novel Mast Cell-Stabilising Amine Derivatives of 3,4-Dihydronaphthalen-
1(2H)-one and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-5-one 
James W. Barlow, Tao Zhang, Orla Woods, Adam J. Byrne and John J. Walsh* 
School of Pharmacy and Pharmaceutical Sciences, University of Dublin, Trinity College, Dublin 2, Ireland 
Abstract: In an investigation of 4-amino-3,4-dihydronaphthalen-1(2H)-ones as novel modulators of allergic and 
inflammatory phenomena, we have investigated a series of cyclic analogues. Tertiary amines of structural types 9, 10, 20 
and 21 were synthesised and evaluated for mast cell stabilising activity. In vitro and in vivo studies showed that of these 
compounds, the cyclohexenylamino derivatives of tetralone and benzosuberone of series 20 and 21 exhibited interesting 
activity both in vitro and in vivo. 
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INTRODUCTION 
Mast cells are densely granulated cells, historically 
associated with the pathogenesis of allergic reactions and 
protective responses to parasites; however, their further roles 
are increasingly being recognised. For example, mast cells 
are involved in cell-mediated immune reactions, are a 
component of the host reaction to infection, and have 
functions in angiogenesis and tissue repair after injury. Much 
interest focuses on their possible involvement in promoting 
persistent inflammation and remodeling in chronic airway 
disease [1]. Apart from lung disease, mast cells have been 
implicated in cardiovascular disease and cancer. Several 
studies point at their role in the pathogenesis
 
of 
atherosclerosis and acute coronary syndromes [2]. Due to the 
association between inflammation and carcinogenesis, a 
possible contribution of these cells to tumour development 
has emerged, and it has been suggested that mast cells may 
even serve as a novel therapeutic target for cancer treatment 
[3]. Drugs in clinical use that modify the degranulation of 
both mast cells and their circulating counterparts the 
basophils include the prototypic agent sodium cromoglycate 
and its analogue nedocromil [4]. Additional agents including 
the cycloheptathiophene ketotifen, the phthalazin-1-one 
azelastine and the propylidene benzoxepin olopatadine 
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exhibit both mast cell stabilising and antihistaminic 
properties, the latter effect mainly attributable to an 
additional diarylalkylamine pharmacophore [5]. It is now 
accepted that although mast cell stabilisation is a clinically 
relevant mechanism of cromoglycate-like drugs, it only 
partially explains the effects of these drugs in vivo and that 
other targets are important: one such is reflected by the 
recent demonstration that they suppress eicosanoid 
generation by promoting the release of the powerful anti-
inflammatory protein annexin-A1 [6]. In addition to 
clinically established drugs, many diverse molecular entities 
have demonstrated both anti-allergic and anti-inflammatory 
activities, including natural products such as flavonoids and 
pterosins. Within the latter class of secondary metabolites, 
indane derivatives based on the indanone pterosin Z have 
been investigated as smooth muscle relaxants [7]; with both 
indanes and aminoindanes showing interesting activity [8]. 
Separately, it is of interest that the dual M2 / H1 receptor 
antagonist dimethindene maleate, possessing a 2-(1H-inden-
2-yl)-ethylamine fragment in its structure, has also been 
shown to modulate mast cell histamine secretion and to 
produce a comparable, dose-dependent inhibition of anti-
IgE-induced histamine release from the same cell type [9]. 
Our earlier work [10] showed that, among a series of 4-
amino-3,4-dihydronaphthalen-1(2H)-ones, the tertiary 
benzylated compound 1 exhibited the most potent activity in 
anti-allergic assays (Fig. 1). In addition, incorporation of the 
second N-benzyl within a second carbocyclic or heterocyclic 
architecture afforded dimeric compounds such as those 
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represented by the general structure 2, and these also 
displayed interesting activities in preliminary screens [11]. In 
the present study, we developed a series of analogous cyclic 
compounds, varying the ring size of both hydroaromatic and 
alicyclic ring components of 1, to investigate whether this 
would result in augmentation or annihilation of the requisite 
activity. There is no literature precedent for these molecules; 
although benzamido derivatives of 6,7,8,9-tetrahydro-(5H)-
benzocycloheptene-5-one have been synthesized by Ritter 
reaction of 6,7-dihydro-(5H)-benzocycloheptene-5-ones with 
benzonitrile [12], and a non-pharmacophoric structural 
aminotetrahydro benzocycloheptenone motif occurs in 
compounds exhibiting effects as diverse as fungicidal [13] 
and 5HT-binding [14] activities.  
CHEMISTRY 
Using analogous methodology to the synthesis of the 
cyclopentyl derivatives [10], we obtained amines 9a-b as 
outlined in Scheme 1. Wohl-Ziegler bromination [15] of 
1,2,3,4-tetrahydro-naphthalen-1-yl acetate gave bromo 
acetate 3. Incorporation of the cyclohexylamino ring was 
achieved by substitution of 3 with cyclohexylamine in basic 
media. Acyl hydrolysis using K2CO3 in methanol followed 
by oxidation with Cr (VI) (Jones reagent) [16] yielded 
ketone 5. Alkylation to 9a-b was accomplished using 
standard N-alkylation conditions [17]. These compounds 
were isolated as diastereomeric mixtures of two enantiomeric 
pairs and were tested as such in the initial assays employed. 
Expansion of the hydroaromatic tetralone ring to that of a 
benzosuberyl moiety was the next synthetic target. 
Compared to 4-bromotetralone, the benzylic monobromide 6 
of benzosuberone [18] is a more stable molecule, so much so 
that nucleophilic substitution with cyclopentylamine 
proceeded slowly and was not a clean transformation, 
producing considerable quantities of imine 7. Acidic 
hydrolysis of the imine followed by methylation afforded 10, 
as shown in Scheme 1. 
Introduction of unsaturation into the cyclohexyl ring of 5 
to yield 18 was accomplished readily by reaction of 3-
bromocyclohexene with 4-amino-3,4-dihydro-2H-
naphthalen-1-one [19] 16 as shown in Scheme 2. Alkylation 
as before gave tertiary amines 20a-f. To complement the 
synthesis and testing of the cyclopentyl-substituted 
tetrahydro-benzocyclohepten-5-one 10, it was decided to 
produce cyclohexenyl-substituted analogues. The synthetic 
rationale for the preparation of these compounds was similar 
to that used to generate 18, namely the reaction of 3-
bromocyclohexene with 9-amino-6,7,8,9-tetrahydro-
benzocyclohepten-5-one 17, which in turn was produced 
from 6, as shown in Scheme 2. As with the compounds of 
series 20, compounds 21a-n were isolated and tested as 
mixtures of stereoisomers.  
PHARMACOLOGY 
Mast Cell Stabilising Activity 
Test compounds were evaluated for inhibition of 
compound 48/80-induced degranulation of rat peritoneal 
mast cells (RPMC), isolated as previously reported [20, 21]. 
Unpurified cell populations as used for initial screening 
(Table 1) were of >90% viability and mast cells comprised 
1.4% of the total cell count, whereas Percoll-purified cells 
(used to determine IC50 values, Table 2) comprised 81.6% of 
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Scheme 1. Synthetic methods for the preparation of 9a-b and 10. 
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the total cell count. The results were compared with the 
reference compound disodium cromoglycate (DSCG). The 
IC50 values of selected compounds (21d-f, 21i, 21l and 21n) 
were determined using both compound 48/80 and the 
calcium ionophore A23187.  
Passive Cutaneous Anaphylaxis (PCA) 
Passive cutaneous anaphylaxis is an immediate type of 
hypersensitivity reaction caused by the interaction of 
antibodies with mast cells of the skin. This technique was 
developed in 1958 by Ovary [22]. In our study, an antiserum 
was raised by means of intraperitoneal inoculation of Wistar 
rats with 1 mL of heat-killed Bordetella pertussis suspension 
(10
10
 organisms per mL) and 0.5 mL of chicken egg albumin 
solution (1 mg per animal) in 0.5M NaCl. After 14 days, the 
animals were exsanguinated and the serum was isolated. The 
prepared serum was intradermally injected, and after 48 
hours, the rats were intravenously challenged via the tail vein 
with 2.5 mg albumin in 0.25 mL 2% Evans Blue, with 
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Scheme 2. Synthetic Methods for the Preparation of 20a-f and 21a-n. 
Table 1. Mast Cell Stabilising Activity of Novel Compounds
a,b 
Compounds % Inhibitor SEM 
9a NI  
9b 99 (NI)
c
 1 
10 NI  
20a 13 8 
20b 68 14 
20c 100  
20d 77 10 
20e 88 (64)
c
 6 (3) 
21f 5 6 
21a NI  
21b 42 7 
21c 99 1 
21d 58 6 
12e 101 10 
21f 24 8 
21h 90 5 
21i 89 7 
21j 95 11 
21k 87 5 
21l 11 4 
21m 91 13 
21n 90 14 
DSCG 10 3 
a
Values are mean of at least n=5, test compounds and DSCG at 2 x 10
-5
M, challenge 
with compound 48/80 at 0.2?g mL-1, 5 min exposure; bNI, no inhibition at 
concentration tested; 
c
Value in brackets reflect anti-IgE as clicitor. 
Table 2. Protective Activity of Selected Compounds Against 
Degranulation of Percoll-purified RPMC Induced by 
Various Elicitors
a,b
 
Compounds Compound 48/80 
Ca
2+
 ionophore 
A23187 
 IC50 (?M) 
21d 1.5 8.2 
21e 7.6 8.4 
21f 1.2 20.7 
21i 2.1 5.6 
21l - 2.6 
21n - 1.8 
a
value are obtained from a mean of four experiments 
b
Calcium ionophore used at 1 ?g mL-1 
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simultaneous injection of 0.25 mL of vehicle (positive 
control) or test compound at a dose of 3 mg kg
-1
. Thirty 
minutes after intravenous injection, the animals were 
sacrificed by cervical dislocation and the skin reflected. The 
vehicle control and test sites were measured and excised, and 
the tissue segments added to 1 mL of 1M KOH. Using the 
method of Katayama [23], the tissue was digested overnight 
at 37 
o
C, and to each digest was added 2.5 mL 0.6M H3PO4 
and 6.5 mL acetone. The tubes were thoroughly shaken, and 
centrifuged at 3000 rpm for 15 minutes. The absorbance of 
each supernatant was measured using UV spectroscopy at 
620 nm. As with the evaluation of mast cell stabilising 
activity, the standard used in this assay was DSCG. 
 
Fig. (2). Effect of novel compounds on PCA. Data were analysed by one-
way ANOVA. Differences among means were considered significant at 
P<0.01. 
RESULTS  
In the preliminary assay with compound 48/80 as mast 
cell degranulating agent (Table 1), N-methyl analogue 9a 
was devoid of any mast cell-stabilising activity. However, N-
benzyl analogue 9b was remarkably effective at the dose 
level which tested (99% inhibition). The compounds of 
series 20 investigated the effect of unsaturation within the 
cyclohexyl ring of 9. Methyl derivative 20a only provided 
13% inhibition of compound 48/80-induced degranulation. 
Allyl derivative 20b offered 68% protection. As with 9b, 20c 
also completely abolished compound 48/80-induced 
degranulation, while substituted benzyl derivatives 20d-e 
also retained activity. Enlargement of the hydroaromatic 
system alone, comparing 9a, 10 and 21a, did not affect mast 
cell-stabilising activity if the nitrogen was substituted with a 
small methyl group. However, in benzosuberone series 21, 
the combination of an enlarged hydroaromatic ring coupled 
with a nitrogen bearing a more bulky planar benzyl or 
substituted benzyl moiety, inhibition was retained or even 
enhanced (20e vs. 21e) in cyclohexenyl-substituted 
derivatives 21b-n, the most active again being benzylated 
compound 21c and substituted benzyl analogues 21e, h-k, 
and m-n. Table 2 shows that while 21e had comparable IC50s 
against 48/80-and ionophore-induced degranulation; the 
other compounds tested showed an appreciable variation in 
protective ability against degranulation caused by ionophore 
A23187, most notably 20f. The results from Fig. 2 show that 
in vivo, while both series 20 and 21 compounds offered 
protective effects, the most active compound tested was 20e, 
inhibiting the reaction by 67%, compared to 28% for the 
unsubstituted benzyl 20c.  
 
Fig. (3). Relationship of inhibitory activity (from Table 1) vs. some 
predicted physicochemical parameters of compounds 21a-n (clogP 
values calculated using MarvinSketch 5.1.4 from ChemAxon). 
DISCUSSION 
Analogously to the cyclopentyl series [10], the most 
active compounds tested in series 9, 20 and 21 were 
benzylated derivatives, reinforcing that a tertiary N-benzyl 
group is a key structural element. Indeed compounds 9a, 10, 
20a and 21a, all containing an N-methyl substituent, were 
largely devoid of activity. Within series 20, contrasting 
somewhat with our earlier study, both allyl and 
trimethoxybenzyl derivatives offered good inhibition of mast 
cell degranulation (68% and 88%, respectively), whereas the 
2?-methylnaphthalenyl derivative 20f did not offer a 
significant protection (5%), in contrast to its N-cyclopentyl 
analogue. Incubation of RPMC suspensions with anti IgE 
caused a rapid (within 10 minutes) release of histamine 
(87%). Compound 20e, unlike 9b, exhibited a protective 
effect against degranulation by this elicitor, more reflective 
of mast cell degranulation in vivo. Use of an in vivo model 
(PCA) revealed that N-cyclopentyl derivative 1 was 
ineffective, despite being a potent inhibitor of compound 
48/80-, Con A- and A23187-induced degranulation [10]. 
Promisingly however, 20e was active against in vivo 
cutaneous anaphylaxis, inhibiting the extravasation reaction 
by 67%. The pattern of results for compounds 21a-n 
mirrored those of series 20, in that bulky benzylated 
substituents on the tertiary nitrogen retained their 
importance. Electronic effects do not appear to be strong 
predictors of in vitro activity, as compounds with either 
electron-donating (e.g. 21e) or electron-withdrawing (e.g. 
21m) groups on the benzyl ring retained activity, and there is 
no obvious correlation between activity and polarizability. 
Fig. 3 shows that lipophilicity may have a role in predicting 
activity within compounds of type 21: all compounds bar 
one that are potent in vitro have a clogP of around 5, obeying 
Lipinski predictors.  
EXPERIMENTAL PROTOCOLS 
All commercially available solvents and reagents were 
used without further purification. Reagents for synthesis and 
biological assays were purchased from Sigma–Aldrich. IR 
spectra were generated on a Perkin Elmer Paragon 1000 FT-
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IR. NMR spectra were generated at Bruker DPX-400 
instrument, at 400.13 MHz for proton (
1
H) magnetic 
resonance and 100.61 MHz (unless otherwise specified) for 
carbon (
13
C) spectra, in chloroform-d. Chemical shifts are 
expressed in ? units (ppm). Low-resolution mass spectra 
were obtained on a Saturn GC/MS 2000 [CP-3800 Gas 
Chromatograph], while high-resolution mass spectra 
(HRMS) were obtained on a Micromass LCT instrument. 
4-(Cyclohexylamino)-1,2,3,4-tetrahydro-1-naphthalenyl 
acetate (4) 
To a solution of 3 [10] (3g, 11.15 mmol) in DCM (10 
mL) was added cyclohexylamine (2.54 mL, 22.3 mmol) and 
triethylamine (2.33 mL, 16.72 mmol). The reaction was 
refluxed for 9 hours, the solvent removed in vacuo, and the 
residue purified by flash column chromatography on silica 
gel (eluant: pet. ether:ethyl acetate, 2:1) to yield the amine as 
a 2:1 mixture of diastereomers, (1.66 g, 52%) a brown oil, 
with the following physical properties: IR (CCl4) ?max 2929, 
2853, 1733, 1450, 1371, 1240, 1020; 
1
H NMR (CDCl3, 400 
MHz) ?ppm = 1.11-1.40 (m, 6H, 3 x CH2), 1.65-2.20 (m, 8H, 4 
x CH2), 2.08 and 2.12 (2 x s, 3H, CH3), 2.30-2.40 (m, 1H, 
NH), 2.66-2.72 (m, 1H, CH2CHCH2), 3.85-3.97 (m, 1H, 
NCHAr), 5.96-6.02 (m, 1H, OCH), 7.21-7.32 (m, 3H, 3 x 
Ar-H), 7.39 and 7.55 (2 x d, 1H, J=7.8Hz, Ar-H); 
13
C NMR 
(CDCl3, 100MHz) ?ppm = Diastereomer 1: 20.96 (CH3), 24.4, 
24.7, 25.4, 25.8, 25.8 (5 x CH2), 33.0, 34.5 (2 x CH2, 
CH2CH2CO), 51.7, 53.7, (2 x CH, CHNHCH), 70.0 (OCH), 
126.5, 127.8, 127.9, 128.1 (4 x tert. C), 134.4, 141.0 (2 x 
quat. C), 170.3 (C=O); Diastereomer 2: 20.98 (CH3), 24.1, 
24.2, 24.5, 24.8, 25.8 (5 x CH2), 33.1, 34.5 (2 x CH2, 
CH2CH2CO), 51.0, 53.7, (2 x CH, CHNHCH), 69.3 (OCH), 
126.7, 128.0, 128.5, 128.9 (4 x tert. C), 134.1, 140.6 (2 x 
quat. C), 170.2 (C=O); MS, m/z, (RI) 288 (M+1, 100), 287 
(M
+
, 18), 229 (13), 100 (13). 
4-(Cyclohexylamino)-1,2,3,4-tetrahydro-1-naphthalen-
one (5) 
To a solution of 4 (1.5 g, 5.23 mmol) in methanol/water 
(10 mL, 1:1) was added excess potassium carbonate (5.0 g, 
36.2 mmol). The reaction was heated under reflux for 1 hour, 
monitoring by GCMS. On completion, the reaction was 
filtered and the solvent removed in vacuo, using toluene to 
azeotropically distill any residual water. To the residue 
containing the alcohol thus obtained, (0.91 g, 71%) was 
added acetone (10 mL) and Jones reagent (5 mL), the latter 
added drop-wise over 30 minutes to the ice-cooled reaction. 
On appearance of the green Cr2(SO4)3, anhydrous sodium 
sulphate (1.5 g, 10.6 mmol) was added. After 2 hours, the 
solvent was evacuated, and the reaction separated using 
ether/water. After three washings with ether (3 x 50 mL), the 
combined organic extracts were filtered and the solvent 
removed in vacuo. The residue was purified by flash column 
chromatography on silica gel (eluant: pet ether:ethyl acetate, 
1:1) to yield the amine as a brown oil (0.49 g, 54%); IR 
(CCl4) ?max ? 2930, 2855, 1690, 1451, 1283; 1H NMR (CDCl3, 
400 MHz) ?ppm = 1.10-1.39 (m, 5H, 5H of CH2), 1.60-1.70 
(m, 1H, 1H of CH2), 1.74-1.84 (m, 2H, 2H of CH2), 1.86-
1.95 (m, 1H, 1H of CH2), 1.98-2.07 (m, 1H, 1H of CH2), 
2.00-2.14 (m, 1H, CH2CHCH2), 2.25-2.35 (m, 2H, NH and 
1H of CH2CH2CO), 2.54 and 2.59 (2 x dd, 1H, J1=6.3Hz, 
J2=4.5Hz, 1H of CH2CO), 2.65-2.75 (m, 1H, 1H of 
CH2CH2CO), 3.00 and 3.04 (2 x dd, 1H, J1=9.5Hz, 
J2=4.5Hz, 1H of CH2CO), 4.08 (dd, 1H, J1=6.4Hz, J2=3.5Hz, 
1H, NCHAr), 7.37 (m, 1H, Ar-H), 7.53-7.57 (m, 2H, 2 x Ar-
H), 8.03 (d, 1H, J=8.0Hz, COAr-H); 
13
C NMR (CDCl3, 
100MHz) ?ppm = 24.5 (CH2), 24.7 (CH2), 25.7 (CH2), 28.4 
(CH2), 33.1 (CH2), 34.3 (CH2), 34.5 (CH2), 51.7 (CH), 53.7 
(CH), 126.7 (tert. C), 127.0 (tert. C), 127.5 (tert. C), 131.5 
(quat. C), 133.2 (tert. C), 146.4 (quat. C), 197.9 (C=O); MS, 
m/z, (RI) 244 (M+1, 100), 100 (10). 
4-[Cyclohexyl(methyl)amino]-1,2,3,4-tetrahydro-1-nap-
hthalenone (9a) 
To a solution of 5 (50 mg, 0.20 mmol) in acetone (10 
mL) was added methyl iodide (0.06 ml, 0.96 mmol) and 
anhydrous potassium carbonate (0.15 g, 1.1 mmol). The 
reaction was stirred at room temperature for 24 hours, and 
filtered. The solvent was removed in vacuo, and the residue 
purified by flash column chromatography on silica gel 
(eluant: pet ether:ethyl acetate, 10:1) to yield the amine as a 
pale oil (46 mg, 88%); IR (CCl4) ?max 2933, 2856, 1692, 
1598, 1452, 1284; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.16-
1.51 (m, 5H, 5H of 5 x CH2), 1.62-1.65 (m, 1H, 1H of 5 x 
CH2), 1.78-1.97 (m, 4H, 4H of 5 x CH2), 2.14-2.24 (m, 5H, 
CH2CH2CO and CH3, a singlet at 2.21), 2.53-2.62 (m, 2H, 
CH2), 2.89 (2 x dd, 1H, J1=5.5Hz, J2=4.5Hz, CH2CHCH2), 
4.16 (dd, 1H, J1=8.9Hz, J2=6.5Hz, NCHAr), 7.35 (dd, 1H, 
J1=8.5Hz, J2=7.5Hz, Ar-H), 7.55 (ddd, 1H, J1=8.4Hz, 
J2=7.5Hz, J3=1.5Hz, Ar-H), 7.80 (d, 1H, J=7.6Hz, Ar-H), 
8.03 (d, 1H, J=7.4Hz, Ar-H); 
13
C NMR (CDCl3, 100MHz) 
?ppm = 24.9 (CH2), 2 x 25.3 (2 x CH2), 25.8 (CH2), 30.4 
(CH2), 30.9 (CH2), 32.6 (CH3), 37.1 (CH2CO), 58.4 (CH), 
59.9 (CH), 126.5 (tert. C), 126.7 (tert. C), 127.4 (tert. C), 2 x 
132.5 (2 x quat. C), 132.9 (tert. C), 197.7 (C=O); MS, m/z, 
(RI) 258 (M+1), 257 (M
+
, 100), 214 (71), 144 (10), 114 (50); 
HRMS (M+H)
+
 258.1864, C17H24NO requires 258.1858. 
4-[Benzyl(cyclohexyl)amino]-1,2,3,4-tetrahydro-1-nap-
hthalenone (9b) 
To a solution of 5 (50 mg, 0.20 mmol) in acetone (10 
mL) was added benzyl bromide (0.12 mL, 1 mmol) and 
anhydrous potassium carbonate (0.15 g, 1.1 mmol). The 
reaction was stirred at reflux for 5 days, and filtered. The 
solvent was removed in vacuo, and the residue purified by 
flash column chromatography on silica gel (eluant: pet 
ether:ethyl acetate, 10:1) to yield the amine as a pale oil (24 
mg, 36%): IR (CCl4) ?max 2932, 2855, 1691, 1599, 1495, 
1452, 1284, 1101; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.06-
1.45 (m, 4H, 4H of CH2), 1.51-1.63 (m, 2H, 2H of CH2), 
1.79-1.82 (m, 2H, 2H of CH2), 1.95-2.04 (m, 2H, 2H of 
CH2), 2.11-2.20 (m, 1H, 1H of CH2), 2.40-2.61 (m, 3H, 3H 
of CH2), 2.84-2.89 (m, 1H, CH), 3.82 and 3.90 (2 x d, 2H, 
J=14.2Hz, NCH2), 4.14-4.17 (m, 1H, NCHAr), 7.24 (dd, 1H, 
J1=8.3Hz, J2=7.5Hz, Ar-H), 7.28-7.61 (m, 6H, 6 x Ar-H), 
8.02-8.06 (m, 2H, 2 x Ar-H); 
13
C NMR (CDCl3, 100MHz) 
?ppm = 25.7 (CH2), 25.8 (CH2), 26.1 (CH2), 26.5 (CH2), 30.6 
(CH2), 32.7 (CH2), 38.1 (CH2CO), 49.8 (NCH2), 56.5 (CH), 
57.2 (CH), 126.3 (tert. C), 126.4 (tert. C), 126.7 (tert. C), 
127.1 (tert. C), 2 x 127.8 (2 x tert. C), 2 x 127.9 (2 x tert. C), 
132.8 (quat. C), 133.0 (tert. C), 140.6 (quat. C), 147.0 (quat. 
C), 197.2 (C=O); MS, m/z, (RI) 334 (M+1), 333 (M
+
, 63), 
290 (38), 242 (45), 190 (100), 146 (33); HRMS (M+H)
+
 
334.2184, C23H28NO requires 334.2171. 
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9-(Cyclopentyl-methyl-amino)-6,7,8,9-tetrahydro-ben-
zocyclohepten-5-one (10) 
To a solution of 8 (1 g, 4.12 mmol) in acetone (10 mL) 
was added methyl iodide (2.92 g, 20.6 mmol) and anhydrous 
potassium carbonate (2 g, 14.5 mmol). The reaction was 
stirred at room temperature for 24 hours, and filtered. The 
solvent was removed in vacuo, and the residue purified by 
flash column chromatography on silica gel (eluant: pet 
ether:ethyl acetate, 10:1) to yield the amine as a pale oil 
(0.92 g, 87%); IR (CCl4) ?max 2957, 2869, 2790, 1687, 1451, 
1279, 1246; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.35-1.53 
(m, 4H, 4H of (CH2)4), 1.53-1.69 (m, 4H, 4H of (CH2)4), 
1.69-2.02 (m, 4H, CH2CH2CH2CO), 2.05 (s, 3H, CH3), 2.50-
2.52 and 2.75-2.90 (2 x m, 2H, CH2CO), 3.00-3.10 (m, 1H, 
CH2CHCH2), 3.75 (dd, 1H, J1=6.5Hz, J2=3.5Hz, NCHAr), 
7.28 (dd, 1H, J1=8.5Hz, J2=7.5Hz, Ar-H), 7.39 (dd, 1H, 
J1=8.5Hz, J2=7.5Hz, Ar-H), 7.48-7.53 (m, 2H, 2 x Ar-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 20.3 (CH2CH2CH2CO), 
24.1 (CH2), 24.2 (CH2), 26.2 (CH2), 26.7 (CH2CH2CH2CO), 
27.9 (CH2), 33.3 (CH3), 40.5 (CH2CO), 61.3 (CH2CHCH2), 
65.2 (NCHAr), 127.0, 127.7 (x2C), 130.7 (4 x tert. C), 139.4 
(quat. C), 143.0 (quat. C), 205.9 (C=O); MS, m/z, (RI) 258 
(M+1, 100), 257 (M
+
, 48), 200 (28); HRMS (M+H)
+
 
258.1873, C17H24NO requires 258.1858. 
tert-Butyl N-(4-oxo-1,2,3,4-tetrahydro-1-naphthalenyl) 
carbamate (14) 
To a solution of azide 12 [10] (3.19 g, 17.1 mmol) in 10 
mL of a mixture of EtOH/EtOAc (1:1) was added di-tert-
butyl dicarbonate (3.74 g, 17.1 mmol) and a catalytic 
quantity of 10% Pd/C. The reaction was stirred overnight 
under an atmosphere of hydrogen. On completion, the 
reaction was filtered to remove the catalyst, and the solvent 
removed in vacuo. The residue was purified by flash column 
chromatography on silica gel (eluant: pet ether:ethyl acetate, 
5:1) to yield the carbamate as a white crystalline solid: IR 
(KBr) ?max ? 2974, 1684, 1508, 1166; 1H NMR (CDCl3, 400 
MHz) ?ppm = 1.45 (s, 9H, (CH3)3), 2.05-2.31 (m, 2H, CH2), 
2.55 and 2.59 (2 x dd, 1H, J1=10.5Hz, J2=4.6Hz, 1H of 
CH2CO), 2.72 and 2.76 (2 x dd, 1H, J1=6.5Hz, J2=4.5Hz, 1H 
of CH2CO), 4.95 (br. s, 1H, CH), 5.19 (br. s, 1H, NH), 7.31 
(dd, 1H, J1=8.5Hz, J2=7.5Hz, Ar-H), 7.39 (d, 1H, J=7.4Hz, 
Ar-H), 7.49 (dd, 1H, J1=8.5Hz, J2=7.4Hz, Ar-H), 7.92 (d, 
1H, J=7.5Hz, COAr-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 
27.9 (3C, 3 x CH3), 29.8 (CH2CHNH), 35.9 (COCH2), 48.4 
(CHNH), 79.3 (C(CH3)3), 126.6, 126.7, 127.4, 133.4 (4 x 
tert. C), 131.3, 143.6 (2 x quat. C), 155.2 (OCO), 196.4 (Ar-
CO); MS, m/z, (RI) 206 (100), 162 (71), 144, (93), 115 (30).  
4-(2-Cyclohexenylamino)-1,2,3,4-tetrahydro-1-naphtha-
lenone (18) 
To a solution of 15 (3.84 g, 14.7 mmol) in DCM (5 mL) 
at 0
o
C was added 5 mL of trifluoroacetic acid (TFA). 
Deprotection afforded amine 16. To a stirred solution of the 
amine in DCM (10 mL) was added triethylamine (4.1 mL, 
29.4 mmol) and 3-bromocyclohexene (3.4 mL, 29.4 mmol). 
The reaction was stirred overnight at room temperature, and 
the solvent removed in vacuo. The residue was purified by 
flash column chromatography on silica gel (eluant: pet 
ether:ethyl acetate, 2:1) to yield the secondary amine, a 
stereoisomeric mixture, as a brown oil (2.11g, 60%): IR 
(KBr) ?max ? 2936, 2863, 1690, 1601, 1450; 1H NMR (CDCl3, 
400 MHz) ?ppm = 1.16 (br., 1H, NH), 1.47-1.66 (m, 2H, 2H 
of CH2), 1.73-1.84 (m, 1H, 1H of CH2), 1.89-1.98 (m, 1H, 
1H of CH2), 1.99-2.06 (m, 2H, CH=CHCH2), 2.07-2.19 and 
2.33-2.28 (2 x m, 2H, CH2CH2CO), 2.51-2.59 and 3.02-3.12 
(2 x m, 2H, CH2CO), 3.30-3.39 (m, 1H, CHCH=CH), 4.08-
4.13 (m, 1H, CHCH2CH2CO), 5.67-5.82 (m, 2H, CH=CH), 
7.35-7.39 (m, 1H, Ar-C5H), 7.46-7.56 (m, 2H, 2 x Ar-H), 
8.02-8.04 (m, 1H, Ar-C8H); 
13
C NMR (CDCl3, 100MHz) 
?ppm = 19.2 and 19.8 (CH2), 2 x 24.9 (CH2), 28.0 and 28.4 
(CH2), 29.0 and 30.3 (CH2), 34.1 and 34.3 (CH2CO), 49.8 
and 50.3 (CH), 52.0 and 52.3 (CH), 126.7 and 126.8 (tert. 
C), 127.1 and 127.2 (tert. C), 2 x 127.6 (tert. C), 128.6 and 
128.8 (tert. C), 129.1 and 129.7 (tert. C), 2 x 131.6 (quat. C), 
2 x 133.1 (tert. C), 145.8 and 146.0 (quat. C), 2 x 197.8 
(C=O); MS, m/z, (RI) 242 (M+1, 100), 98 (15). 
General procedure for the preparation of tertiary amines 
(20a–f)  
Amines 20a–f were prepared by adding equimolar 
quantities of appropriate alkyl halide and anhydrous 
potassium carbonate to an acetone solution (10 mL) of 18. 
The reaction was stirred at room temperature for 1-7 days, 
and filtered. The solvent was removed in vacuo, and the 
residue purified by flash column chromatography on silica 
gel (eluant: pet ether:ethyl acetate, 10:1) to yield amines 
20a–f, as oils, which were routinely converted to their 
hydrochloride salts. 
4-[2-Cyclohexenyl(methyl)amino]-1,2,3,4-tetrahydro-1-
naphthalenone (20a) 
Yield: 72%; IR (CCl4) ?max ? 2933, 1689, 1598, 1452, 
1329, 1284, 1041; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.50-
1.78 (m, 2H, CH2CH2CH2), 1.81-1.89 (m, 2H, 
CH2CH2CH2CHN), 1.95-2.04 (m, 2H, COCH2CH2), 2.19-
2.25 (m, 5H, C=CCH2 and CH3), 2.52-2.61 (m, 1H, COCH2), 
2.87 and 2.91 (2 x dd, 1H, J1=5.5, J2=5Hz, COCH2), 3.30 
and 3.46 (2 x br., 1H, NCHC=C), 4.05-4.12 (m, 1H, 
CHCH2CH2CO), 5.71-5.73 (m, 1H, CH=CH), 5.81-5.84 (m, 
1H, CH=CH), 7.33-7.36 (m, 1H, Ar-H), 7.52-7.56 (m, 1H, 
Ar-H), 7.74-7.78 (m, 1H, Ar-H), 8.00-8.03 (m, 1H, Ar-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 21.0 and 21.1, 24.7 and 
24.8, 25.5 and 25.8, 25.9 and 26.2 (4 x CH2), 32.0 and 33.0 
(CH3), 36.7 and 36.8 (CH2CO), 56.9 and 57.1 (CH), 58.4 and 
59.7 (CH), 126.60 and 126.62 (tert. C), 2 x 126.7 (tert. C), 
127.3 and 127.6 (tert. C), 129.5 and 129.7 (tert. C), 130.1 
and 130.7 (tert. C), 132.80 and 132.83 (tert. C), 2 x 132.4 
(quat. C), 146.3 and 146.4 (quat. C), 2 x 197.6 (C=O); MS, 
m/z, (RI) 256 (M+1, 8), 255 (M
+
, 8), 227 (100), 112 (17), 68 
(23); HRMS (M+H)
+
 256.1692, C17H22NO requires 
256.1701. 
4-[Allyl(2-cyclohexenyl)amino]-1,2,3,4-tetrahydro-1-
naphthalenone (20b) 
Yield: 66%; IR (CCl4) ?max 2933, 2863, 1691, 1598, 
1452, 1286; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.48-1.67 
(m, 2H of CH2CH2CH2), 1.74-2.06 (m, 4H of CH2CH2CH2), 
2.07-2.19 (m, 1H of CH2CH2CO), 2.26- 2.41 (m, 1H of 
CH2CH2CO), 2.51-2.62 (m, 1H of CH2CO), 2.82-2.89 (m, 
1H of CH2CO), 3.27-3.54 (m, 3H, NCH2 and NCHC=C), 
4.21-4.25 (m, 1H, CHCH2CH2CO), 5.06-5.09 (m, 1H, 1H of 
CH=CH2), 5.17-5.24 (m, 1H, 1H of CH=CH2), 5.68-5.92 (m, 
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3H, CH=CH and CH=CH2), 7.32-7.36 (m, 1H, Ar-H), 7.55-
7.59 (m, 1H, Ar-H), 7.92-7.96 (m, 1H, Ar-H), 8.02-8.04 (m, 
1H, Ar-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 21.5 and 
21.8, 24.6 and 24.7, 26.2 and 26.4, 27.9 and 29.1, 2 x 38.1 (5 
x CH2), 48.8 and 49.0 (CH2CO), 53.7 and 54.2 (CH), 56.4 
and 57.5 (CH), 115.5 and 115.8 (CH2=C), 126.39 and 
126.42, 126.72 and 126.78, 126.95 and 127.06, 129.8 and 
130.0, 129.9 and 132.1, 133.0 and 133.1, 137.8 and 138.0 (7 
x tert. C), 2 x 132.7 (quat. C), 2 x 147.4 (quat. C), 2 x 197.3 
(C=O); MS, m/z, (RI) 282 (M+1, 34), 281 (M
+
, 34), 253 
(83), 225 (37), 138 (100); HRMS (M+H)
+
 282.1877, 
C19H24NO requires 282.1858. 
4-[Benzyl(2-cyclohexenyl)amino]-1,2,3,4-tetrahydro-1-
naphthalenone (20c) 
Yield: 63%; IR (CCl4) ?max 2934, 1691, 1598, 1453, 
1285; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.48-1.59 (m, 1H, 
1H of CH2CH2CH2), 1.64-1.86 (m, 2H, 2H of CH2CH2CH2), 
1.91-2.09 (m, 3H, 3H of CH2CH2CH2), 2.07-2.23 (m, 1H, 
1H of CH2CH2CO), 2.41-2.58 (m, 2H; 1H of CH2 and 1H of 
CH2CO), 2.84-2.90 (m, 1H, 1H of CH2CO), 3.34-3.36 and 
3.45-3.49 (2 x br. m, 1H, NCHC=C), 3.81-3.95 (m, 2H, 
NCH2), 4.12 and 4.19 (2 x dd, 1H, J1=11Hz, J2=3.5Hz, 
CHCH2CH2CO), 5.80-5.89 (m, 2H, CH=CH), 7.23-7.28 (m, 
1H, Ar-H), 7.31-7.36 (m, 3H, 3 x Ar-H), 7.42-7.48 (m, 2H, 2 
x Ar-H), 7.57-7.63 (m, 1H, Ar-H), 8.01-8.05 (m, 2H, 2 x Ar-
H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 21.5 and 21.9, 2 x 
24.6, 25.3 and 26.3, 27.2 and 29.5 (4 x CH2), 38.0 and 38.1 
(CH2CO), 49.7 and 49.9 (NCH2), 53.2 and 53.5 (CH), 56.6 
and 57.7 (CH), 2 x 126.4, 2 x 126.5, 126.78 and 126.84, 2 x 
127.0, (4 x tert. C), 127.8-128.0 (4 x tert. C, signal overlap), 
129.7 and 130.3, 130.2 and 132.1 (2 x tert. C), 132.7 and 
132.8 (quat. C), 133.0 and 133.1 (tert. C), 2 x 140.7, 2 x 
146.6 (2 x quat. C), 197.18 and 197.23 (C=O); MS, m/z, (RI) 
303 (100), 212 (19), 188 (42), 158 (19), 144 (15); HRMS 
(M+H)
+
 332.2007, C23H26NO requires 332.2014. 
4-[2-Cyclohexenyl(4-methylbenzyl)amino]-1,2,3,4-tetra-
hydro-1-naphthalenone (20d) 
Yield: 18%; IR (CCl4) ?max 2934, 1691, 1598, 1514, 
1453, 1330, 1284, 1150, 1022; 
1
H NMR (CDCl3, 400 MHz) 
?ppm = 1.47-1.62 (m, 1H, 1H of CH2), 1.66-2.23 (m, 6H, 6H 
of CH2), 2.36 x 2 (2 x s, 3H, CH3), 2.44-2.57 (m, 2H, 2H of 
CH2), 2.87-2.91 (m, 1H, 1H of COCH2), 3.36 and 3.49 (2 x 
br., 1H, NCHC=C), 3.79-3.93 (m, 2H, NCH2), 4.14 and 4.20 
(2 x dd, 1H, J1=11Hz, J2=3Hz, CHCH2CH2CO), 5.83-5.90 
(m, 2H, CH=CH), 7.16-7.18 (m, 2H, 2 x Ar-H), 7.33-7.39 
(m, 3H, 3 x Ar-H), 7.59-7.64 (m, 1H, Ar-H), 8.04-8.09 (m, 
2H, Ar-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 2 x 20.6 
(CH3), 21.5 and 22.0, 2 x 24.7, 25.3 and 26.3, 27.3 and 29.5 
(4 x CH2), 38.1 and 38.2 (COCH2), 49.4 and 49.6 (NCH2), 
53.1 and 53.4, 56.5 and 57.6 (2 x CH), 126.42 and 126.44, 
126.77 and 126.84, 2 x 127.1, 2 x 127.8, 2 x 128.0, 128.6 
(2C) (7 x tert. C, signal overlap), 129.9 and 130.1, 130.2 and 
132.3, 133.0 and 133.2 (3 x tert. C), 132.7 and 132.8, 2 x 
135.9, 136.9 and 137.6, 146.7 and 147.1 (4 x quat. C), 197.1 
and 197.2 (C=O); MS, m/z, (RI) 346 (M+1, 5), 317 (100), 
202 (44), 105 (26); HRMS (M+H)
+
 346.2146, C24H28NO 
requires 346.2171. 
4-(2-Cyclohexenyl-3,4,5-trimethoxyanilino)-1,2,3,4-tet-
rahydro-1-naphthalenone (20e) 
Yield: 14%; IR (CCl4) ?max 2935, 1693, 1591, 1505, 
1464, 1419, 1329, 1236, 1132, 1011; 
1
H NMR (CDCl3, 400 
MHz) ?ppm = 1.45-1.58 (m, 1H, 1H of CH2), 1.61-1.73 (m, 
1H, 1H of CH2), 1.75-1.85 (m, 1H, 1H of CH2), 1.89-2.06 
(m, 3H, 3H of CH2), 2.08-2.21 (m, 1H, 1H of CH2), 2.38-
2.53 (m, 2H, 2H of CH2), 2.82-2.90 (m, 1H, 1H of CH2), 
3.35 and 3.49 (2 x br., 1H, NCHC=C), 3.73-3.93 (m, 11H, 3 
x OCH3 and NCH2, with 3 x OCH3 at 3.82, 3.84 and 3.85), 
4.09-4.19 (m, 1H, CHCH2CH2CO), 5.77-5.88 (m, 2H, 
CH=CH), 6.65 (s, 1H, (CH3O)3Ar-H), 6.70 (s, 1H, 
(CH3O)3Ar-H), 7.28-7.34 (m, 1H, Ar-H), 7.54-7.59 (m, 1H, 
Ar-H), 7.97-8.05 (m, 2H, 2 x Ar-H); 
13
C NMR (CDCl3, 
100MHz) ?ppm = 21.4 and 21.9 (CH2), 2 x 24.6 (CH2), 25.4 
and 26.3 (CH2), 27.2 and 29.4 (CH2), 37.90 and 37.95 
(CH2CO), 50.00 and 50.05 (NCH2), 53.3 and 53.6 (CH), 55.6 
and 60.3 (3 x OCH3, signal overlap), 56.8 and 57.8 (CH), 2 x 
104.3, 2 x 104.5 (2 x (CH3O)3-ArCH), 2 x 126.6, 126.7 and 
126.88, 2 x 126.90, 129.6 and 130.2, 130.5 and 131.8, 
132.86 and 132.90 (6 x tert. C), 2 x 132.79, 2 x 135.9, 136.3 
and 136.5, 146.4 and 146.6, 2 x 152.68, 2 x 152.72 (6 x quat. 
C), 196.95 and 197.04 (C=O); MS, m/z, (RI) 422 (M+1, 1), 
421 (M
+
,1), 240 (75), 181 (100), 117 (8); HRMS (M+H)
+
 
422.2329, C26H32NO4 requires 422.2331. 
4-[2-Cyclohexenyl(2-naphthylmethyl)amino]-1,2,3,4-
tetrahydro-1-naphthalenone (20f) 
Yield: 43%; IR (CCl4) ?max 2935, 1692, 1598, 1285; 1H 
NMR (CDCl3, 400 MHz) ?ppm = 1.46-2.27 (m, 7H, 7H of 
CH2), 2.46-2.62 (m, 2H, CH2), 2.83-2.93 (m, 1H, 1H of 
CH2), 3.40 and 3.51 (2 x br., 1H, CH), 3.98-4.10 (m, 2H, 
NCH2), 4.16 and 4.23 (2 x br.d, 1H, J=11Hz, CH), 5.85-5.94 
(br., 2H, CH=CH), 7.31-7.37 (m, 1H, Ar-H), 7.42-7.51 (m, 
2H, 2 x Ar-H), 7.59-7.69 (m, 2H, 2 x Ar-H), 7.78-7.87 (m, 
4H, 4 x Ar-H), 8.00-8.04 (m, 1H, Ar-H), 8.07 and 8.10 (2 x 
d, 1H, J=8Hz, Ar-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 
21.5 and 21.9, 2 x 24.6, 25.3 and 26.4, 27.2 and 29.5 (4 x 
CH2), 38.05 and 38.15 (CH2CO), 50.0 and 50.1 (NCH2), 53.2 
and 53.6, 56.6 and 57.6 (2 x CH), 2 x 125.0, 2 x 125.5, 126.2 
and 126.3, 126.4 and 126.5, 126.5 and 126.6, 126.8 and 
126.9, 2 x 127.0, 2 x 127.1, 2 x 127.2, 2 x 127.6, 129.7 and 
130.3, 130.4 and 132.1, 133.0 and 133.2 (13 x tert. C), 132.3 
and 132.7, 132.8 and 132.9, 2 x 137.5, 2 x 138.1, 146.5 and 
146.8 (5 x quat. C), 2 x 197.1 (C=O); MS, m/z, (RI) 382 
(M+1, 2), 381 (M
+
, 2), 353 (83), 240 (72), 208 (43), 141 
(100), 115 (69); HRMS (M+H)
+
 382.2156, C27H27NO 
requires 382.2171. 
9-(Cyclohex-2-enylamino)-6,7,8,9-tetrahydro-benzocyc-
lohepten-5-one (19) 
To a solution of 17 (2.4 g, 13.7 mmol) in DCM (10 mL) 
was added 3-bromocyclohexene (1.57 mL, 13.7 mmol), and, 
dropwise, triethylamine (3.83 mL, 27.4 mmol). The reaction 
was stirred at reflux for twelve hours. The reaction mixture 
was then partitioned between 2M HCl (25 mL) and diethyl 
ether (3 x 20 mL), and the organic layers discarded. The 
aqueous layer was basified with 2M NaOH and extracted 
with diethyl ether (3 x 20 mL). The re-basified organic 
extract was columned on silica gel (eluant: pet ether:ethyl 
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acetate, 5:1) to yield the amine, a mixture of isomers, as a 
pale yellow oil (2.17g, 62%): IR (CCl4) ?max 2933, 2862, 
1685, 1601, 1449, 1244, 1103; 
1
H NMR (CDCl3, 400 MHz) 
?ppm = 1.01 (br., 1H, NH), 1.15-1.42 (m, 2H, 2H of CH2), 
1.50-1.58 (m, 1H, 1H of CH2), 1.60-1.74 (m, 4H, 4H of 
CH2), 1.80-1.89 (m, 2H, 2H of CH2), 1.93-2.02 (m, 1H, 1H 
of CH2), 2.45 and 2.49 (2 x d, 1H, J~4.5Hz, 1H of CH2CO), 
2.70-2.78 (br. m, 1H, NCHC=C), 2.85 and 2.90 (2 x d, 1H, 
J~9.1Hz, 1H of CH2CO), 4.15-4.19 (m, 1H, NCHAr), 5.46-
5.72 (m, 2H, CH=CH), 7.24-7.43 (m, 4H, 4 x Ar-H); 
13
C 
NMR (CDCl3, 100MHz) ?ppm = 19.3 and 19.7 (CH2), 19.8 
and 19.9 (CH2), 24.7 and 24.8 (CH2), 27.8 and 29.6 (CH2), 
32.2 and 32.4 (CH2), 40.5 and 40.6 (CH2), 48.8 and 49.3 
(CH), 56.3 and 56.9 (CH), 126.4 and 126.5 (tert. C), 2 x 
127.1 (tert. C), 2 x 127.4 (tert. C), 128.0 and 128.2 (tert. C), 
128.6 and 130.1 (tert. C), 130.69 and 130.72 (tert. C), 2 x 
138.7 (quat. C), 141.1 and 141.5 (quat. C), 2 x 206.9 (C=O); 
MS, m/z, (RI) 256 (M+1, 100), 255 (M
+
, 24); HRMS 
(M+H)
+
 256.1691, C17H22NO requires 256.1701. 
General procedures for the preparation of tertiary amines 
(21a–n)  
Amines 21a–e were prepared analogously to 20a-f. For 
21f-n, to a stirred solution of 19 in acetonitrile (8 mL) was 
added appropriate alkyl halide (1.1 equiv.) and N,N-
diisopropylethylamine (1.5 equiv.). The resulting mixture 
was heated to gentle reflux and kept under an atmosphere of 
nitrogen. After 1-12 days, the reaction solutions were 
quenched by the addition of 2M aq. HCl (20 mL) and the 
product was extracted with diethyl ether (3 x 25mL). The 
combined organic extracts were dried over magnesium 
sulphate, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (eluant: 
hexane:ethyl acetate). All homogenous fractions were 
collected and the solvent evaporated to afford a 
stereoisomeric mixture of the title compounds, as oils, which 
were routinely converted to their hydrochloride salts. 
9-(Cyclohex-2-enyl-methyl-amino)-6,7,8,9-tetrahydro-
benzocyclohepten-5-one (21a) 
Yield: 79%; IR (CCl4) ?max 2934, 1686, 1450, 1278, 
1245, 1008; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.38-2.29 
(m, 10H, 5 x CH2), 1.97 and 2.23 (2 x s, 3H, CH3), 2.50 and 
2.54 (2 x dd, 1H, J1~7.5Hz, J2~3Hz, 1H of CH2CO), 2.87-
3.01 (m, 2H, 1H of CH2CO and CH), 3.81-3.86 (m, 1H, CH), 
5.38 and 5.56 (2 x d, 1H, J=10Hz, 1H of CH=CH), 5.70 and 
5.79 (2 x m, 1H of CH=CH), 7.28-7.49 (m, 4H, 4 x Ar-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 19.58 and 19.64, 20.0 
and 21.1, 21.4 and 22.1, 24.6 and 24.7, 26.5 and 26.8 (5 x 
CH2), 33.3 and 33.6 (CH3), 39.7 and 39.8 (CH2CO), 54.6 and 
54.8 (CH), 63.9 and 64.3 (CH), 126.8 and 127.05, 127.07 
and 127.12, 127.37 and 127.43, 128.6 and 128.8, 129.2 and 
130.3, 130.4 and 130.8 (6 x tert. C), 139.0 and 139.2, 141.2 
and 141.9 (2 x quat. C), 206.1 and 206.4 (C=O); MS, m/z, 
(RI) 270 (M+1, 37), 269 (M
+
, 16), 241 (67), 213 (100); 
HRMS (M+H)
+
 270.1850, C18H24NO requires 270.1858. 
9-(Allyl-cyclohex-2-enyl-amino)-6,7,8,9-tetrahydro-
benzocyclohepten-5-one (21b) 
Yield: 30%; IR (CCl4) ?max 2934, 2865, 1686, 1458, 
1280, 1242; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.31-1.53 
(m, 2H, 2H of CH2), 1.69-2.14 (m, 8H, 4 x CH2), 2.52-2.68 
(m, 1H, 1H of CH2CO), 2.80-2.96 (m, 1H, 1H of CH2CO), 
3.10-3.52 (m, 3H, NCH2 and CHCH=CH), 4.11-4.16 (m, 1H, 
NCHAr), 4.95-5.15 (m, 2H, CH2=CH), 5.54-5.63 (m, 1H, 1H 
of CH=CH), 5.71-5.80 (m, 1H, 1H of CH=CH), 5.79-5.98 
(m, 1H, CH2=CH), 7.27-7.34 (m, 1H, Ar-H), 7.40-7.46 (m, 
1H, Ar-H), 7.51 and 7.69 (dd and d, 1H, J1dd=7.5, 
J2dd=1.5Hz, Jd=7.5Hz, COAr-H), 7.54-7.59 (m, 1H, Ar-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 20.0 and 21.0 (CH2), 
21.5 and 21.6 (CH2), 24.7 and 24.8 (CH2), 25.1 and 25.5 
(CH2), 28.2 and 29.3 (CH2), 40.1 and 40.2 (CH2CO), 49.7 
and 50.3 (CH2N), 55.1 and 55.3 (CH), 60.3 and 61.3 (CH), 
114.8 and 115.0 (CH2=CH), 126.5 and 126.7, 127.2 and 
127.4, 127.4 and 127.7, 129.2 and 129.8, 2 x 130.2, 130.6 
and 130.7, 138.6 and 139.0 (7 x tert. C), 2 x 138.0, 142.6 and 
143.8 (2 x quat. C), 205.5 and 206.3 (C=O); MS, m/z, (RI) 
296 (M+1, 100), 295 (M
+
, 18), 267 (22), 211 (24), 131 (19); 
HRMS (M+H)
+
 296.2006, C20H26NO requires 296.2014. 
9-(Benzyl-cyclohex-2-enyl-amino)-6,7,8,9-tetrahydro-
benzocyclohepten-5-one (21c) 
Yield: 25%; IR (CCl4) ?max ??2933, 2864, 1686, 1599, 
1495, 1453, 1280, 1124; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 
1.30-2.28 (m, 10H, 5 x CH2), 2.52-2.68 (m, 1H, 1H of 
CH2CO), 2.71-2.80 (m, 1H, 1H of CH2CO), 3.35 and 3.42 (2 
br., 1H, CHCH=CH), 3.76-4.02 (m, 2H, NCH2), 4.17-4.24 
(m, 1H, NCHAr), 5.69-5.87 (m, 2H, CH=CH), 7.22-7.28 (m, 
1H, Ar-H), 7.32-7.38 (m, 3H, 3 x Ar-H), 7.44-7.63 (m, 4H, 4 
x Ar-H), 7.86 and 7.96 (2 x d, 1H, J=7.5Hz, COAr-H); 
13
C 
NMR (CDCl3, 100MHz) ?ppm = 20.0 and 20.3, 21.6 and 21.7, 
24.7 and 24.8, 25.0 and 26.5, 29.1 and 29.9 (5 x CH2), 40.2 
and 40.3 (CH2CO), 50.8 and 51.6 (NCH2), 55.2 and 55.3, 
60.9 and 61.5 (2 x CH), 126.06 and 126.11, 126.5 and 126.6, 
127.2 and 127.3, 127.4 and 127.53, 127.53 and 127.66, 
127.66 and 127.68, 127.8 (2C), 129.8 and 129.9, 2 x 130.2, 2 
x 130.9 (11 x tert. C), 138.8 and 138.9, 141.1 and 141.8, 
142.7 and 143.7 (3 x quat. C), 205.6 and 206.5 (C=O); MS, 
m/z, (RI) 346 (M+1, 100), 345 (M
+,
 28), 317 (61), 289 (47), 
266 (54), 246 (24), 186 (100), 158 (21); HRMS (M+H)
+
 
346.2186, C24H28NO requires 346.2171. 
9-[Cyclohex-2-enyl-(2,3,4-trimethoxy-benzyl)-amino]-
6,7,8,9-tetrahydro-benzocyclohepten-5-one (21d) 
Yield: 54%; IR (DCM) ?max 3396, 3063, 2938, 1683, 
1600, 1466, 1287, 1101; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 
1.37-2.23 (4 x m, 10H, 5 x CH2), 2.52-2.65 (m, 1H, 1H of 
CH2CO), 2.68-2.75 (m, 1H, 1H of CH2CO), 3.31 (br. m, 1H, 
NCHCH=CH), 3.68-3.86 (m, 2H, NCH2), 3.87-3.89 (s 
overlapping, 9H, 3 x OCH3), 4.13-4.18 (m, 1H, NCHAr), 
5.65-5.80 (m, 2H, CH=CH), 6.72 (d, 1H, J=9.04Hz, Ar-H), 
7.27 and 7.28 (1 x d, 1H, J=4.52Hz and 1 x d, J= 4.0Hz, Ar-
H), 7.31-7.36 (m, 1H, Ar-H), 7.44-7.59 (m, 2H, 2 x Ar-H), 
7.82 and 7.89 (2 x d, 1H, J=7.76Hz, COAr-H); 
13
C NMR 
(CDCl3, 100MHz) ?ppm = 20.5 and 20.8 (CH2), 22.1 and 22.2 
(CH2), 25.1 and 25.2 (CH2), 25.4 and 27.1 (CH2), 29.2 and 
30.2 (CH2), 40.6 and 40.7 (CH2), 44.3 and 44.9 (CH2), 55.3 
and 55.4 (CH), 55.5, 60.3, 60.4 (3 x OCH3), 60.7 and 61.1 
(CH), 2 x 106.8 (tert. C), 123.3 and 123.5 (tert. C), 126.4 and 
126.5 (tert. C), 126.6, 127.1, 127.2, 127.3 (1 x tert. C and 1 x 
quat. C), 127.4 and 127.5 (tert. C), 129.8, 129.9, 130.1, 
130.3 (CH=CH), 2 x 131.3 (tert. C), 138.6 and 138.8 (quat. 
C), 2 x 141.4 (quat. C), 142.9 and 143.8 (quat. C), 150.8 and 
151.1 (quat. C), 151.6 and 151.7 (quat. C), 206.1 and 206.9 
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(C=O); HRMS (M+H)
+
 436.2480, C27H34NO4 requires 
436.2488. 
9-[Cyclohex-2-enyl-(3,4,5-trimethoxy-benzyl)-amino]-6, 
7,8,9-tetrahydro-benzocyclohepten-5-one (21e) 
Yield: 59%; IR (DCM) ?max 3400, 3053, 2939, 1683, 
1594, 1463, 1254, 1126; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 
1.40-2.16 (5 x m, 10H, 5 x CH2), 2.53-2.58 (m, 1H, 1H of 
CH2CO), 2.73-2.80 (m, 1H, 1H of CH2CO), 3.30-3.36 (br. 
m, 1H, NCHCH=CH), 3.67-3.83 (m, 2H, NCH2), 3.85 (s 
overlapping, 3H, OCH3), 3.89 (s overlapping, 6H, 2 x 
OCH3), 4.14-4.19 (m, 1H, NCHAr), 5.65-5.79 (m, 2H, 
CH=CH), 6.63 and 6.66 (2 x s, 2H, 2 x Ar-H), 7.32 and 7.34 
(1 x d, 1H, J=7.52Hz, and 1 x d, J=7.56Hz, Ar-H), 7.45-7.55 
(m, 2H, 2 x Ar-H), 7.77 (2 x d, 1H, J=7.78Hz, COAr-H); 
13
C 
NMR (CDCl3, 100MHz) ?ppm = 20.4 and 20.6 (CH2), 22.0 
and 22.1 (CH2), 25.1 and 25.2 (CH2), 25.4 and 27.1 (CH2), 
29.2 and 29.9 (CH2), 40.6 and 40.7 (CH2), 51.7 and 52.4 
(CH2), 55.7 and 55.8 (CH), 3 x 56.0 (3 x OCH3), 60.9 and 
62.2 (CH), 2 x 103.8 (tert. C), 2 x 104.0 (tert. C), 2 x 126.8 
(tert. C), 127.0 and 127.2 (tert. C), 127.4 and 127.6 (tert. C), 
129.0, 130.0, 130.1 and 130.4 (CH=CH), 130.7 and 130.8 
(tert. C), 2 x 135.8, 137.0 and 137.6, 138.8 and 140.0, 142.4 
and 143.0 (4 x quat. C), 4 x 152.6 (2 x quat. C), 206.2 and 
206.8 (C=O); HRMS (M+Na)
+
 458.2307, C27H33NO4Na 
requires 458.2322. 
9-[Cyclohex-2-enyl-(4-trifluoromethoxy-benzyl)-amino ]-
6,7,8,9-tetrahydro-benzocyclohepten-5-one (21f) 
Yield: 81%; IR (DCM) ?max 3401, 3058, 2923, 1682, 
1451, 1296, 1161; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.39-
2.18 (4 x m, 10H, 5 x CH2), 2.55-2.63 (m, 1H, 1H of 
CH2CO), 2.67-2.75 (m, 1H, 1H of CH2CO), 3.35-3.41 (br. 
m, 1H, NCHCH=CH), 3.72-3.93 (m, 2H, NCH2), 4.14-4.17 
(m, 1H, NCHAr), 5.64-5.79 (m, 2H, 2H of CH=CH), 7.16 (2 
x overlapping t, 2H, J=7.04Hz, 2 x Ar-H), 7.30 (dd, 1H, 
J1=13.56Hz, J2=6.52Hz, Ar-H), 7.38 (d, 1H, J=8.52Hz, Ar-
H), 7.42-7.53 (m, 3H, 3 x Ar-H), 7.76 and 7.82 (2 x d, 1H, 
J=8.04Hz, COAr-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 
19.9 and 20.1 (CH2), 21.4 and 21.5 (CH2), 24.6 and 24.7 
(CH2), 24.8 and 26.1 (CH2), 29.0 and 29.6 (CH2), 40.2 and 
40.3 (CH2), 50.3 and 50.9 (CH2), 55.3 and 55.4 (CH), 61.4 
and 61.7 (CH), 116.2, 118.8, 121.3 and 123.9 (OCF3, q, 
JCF=252.3Hz), 4 x 120.3 (2 x tert. C), 126.7, 126.8, 127.0, 
127.2, 127.3, 127.7, (3 x tert. C), 2 x 128.5 (tert. C), 2 x 
128.7 (tert. C), 129.4, 129.8, 130.2, 130.5 (CH=CH) 2 x 
130.9 (tert. C), 138.7 and 138.9 (quat. C), 139.9 and 140.7 
(quat. C), 142.2 and 143.0 (quat. C), 2 x 147.3 (Ar-COCF3), 
205.8 and 206.6 (C=O); HRMS (M+Na)
+
 452.1813, 
C25H26NO2F3 requires 452.1813. 
9-[Cyclohex-2-enyl-(3-trifluoromethoxy-benzyl)-amino]-
6, 7,8,9-tetrahydro-benzocyclohepten-5-one (21g) 
Yield: 73%; IR (DCM) ?max 3063, 2925, 1688, 1450, 
1261, 1216, 1164; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.40-
2.21 (4 x m, 10H, 5 x CH2), 2.55-2.66 (m, 1H, 1H of 
CH2CO), 2.69-2.77 (m, 1H, 1H of CH2CO), 3.37-3.41 (br. 
m, 1H, NCHC=C), 3.75-3.98 (m, 2H, NCH2), 4.15-4.19 (m, 
1H, NCHAr), 5.65-5.82 (m, 2H, CH=CH), 7.07-7.09 (m, 1H, 
Ar-H), 7.27-7.39 (m, 4H, 4 x Ar-H), 7.48-7.56 (m, 2H, 2 x 
Ar-H), 7.79 and 7.85 (2 x d, 1H, J=7.76Hz, COAr-H); 
13
C 
NMR (CDCl3, 100MHz) ?ppm = 20.3 and 20.6 (CH2), 21.9 
and 22.0 (CH2), 25.1 and 25.2 (CH2), 25.4 and 26.7 (CH2), 
29.7 and 30.3 (CH2), 40.6 and 40.8 (CH2), 50.9 and 51.5 
(CH2), 55.8 and 55.9 (CH), 61.7 and 61.9 (CH), 2 x 118.9 
(tert. C), 116.7, 119.3, 121.2 and 124.3 (OCF3, q, 
JCF=255.6), 120.1 and 120.3 (tert. C), 126.1 and 126.2 (tert. 
C), 127.2, 127.3, 127.4, 127.6, 127.8, 128.1 (3 x tert. C), 2 x 
129.5 (tert. C) 129.8, 130.2, 130.9, 131.1 (CH=CH) 131.4 
and 131.5 (tert. C), 139.1 and 139.3 (quat. C), 142.3 and 
143.4 (quat. C), 144.3 and 145.1 (quat. C), 149.3 (Ar-
COCF3), 206.3 and 207.1 (C=O); HRMS (M+Na)
+
 
452.1813, C25H26NO2F3 requires 452.1813. 
9-[Cyclohex-2-enyl-(2,3,6-trifluoro-benzyl)-amino]-6,7, 
8,9-tetrahydro-benzocyclohepten-5-one (21h) 
Yield: 70%; IR (DCM) ?max 3400, 3058, 3019, 2930, 
1684, 1496, 1246, 1033; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 
1.39-2.42 (3 x m, 10H, 5 x CH2), 2.61-2.76 (m, 2H, CH2CO), 
3.27-3.47 (br. m, 1H, NCHCH=CH), 3.81-4.06 (2 x m, 3H, 
NCH2 and NCHAr), 5.74-5.85 (m, 2H, CH=CH), 6.72-6.81 
(m, 1H, Ar-H), 6.97-7.07 (m, 1H, Ar-H), 7.23-7.29 (m, 1H, 
Ar-H), 7.42 (t, 1H, J=7.34Hz, Ar-H), 7.52 (dd, 1H, 
J1=2.51Hz, J2=5.02Hz, Ar-H), 7.83 and 7.88 (2 x d, 1H, 
J=7.56Hz, COAr-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 
20.6 and 20.7 (CH2), 22.0 and 22.2 (CH2), 25.0 and 25.1 
(CH2), 25.4 and 27.1 (CH2), 28.8 and 30.1 (CH2), 2 x 39.1 
(CH2), 40.8 and 41.0 (CH2), 55.7 and 55.9 (CH), 61.1 and 
61.7 (CH), 110.2-110.6 (tert. C), 115.4-115.7 (tert. C), 
117.8-118.0 (quat. C), 118.4-118.7 (quat. C), 126.7 and 
126.2 (tert. C), 127.6 and 127.8 (tert. C), 2 x 128.4 (Ar-
CHCCO), 129.6, 130.4, 130.6 (CH=CH), 2 x 130.9 (tert. C), 
131.6 (CH=CH), 139.1 and 139.3 (quat. C), 143.7 and 144.1 
(quat. C), 146.1 and 147.7 (2 x t, JCF=161.9, CF), 148.6 and 
150.2 (2 x m, JCF ~160Hz, CF), 156.2 and 157.8 (d, JCF= 
161.9Hz, CF), 206.3 and 207.1 (C=O); HRMS (M+H)
+
 
400.1877, C25H25NOF3 requires 400.1697. 
4-{[Cyclohex-2-enyl-(9-oxo-6,7,8,9-tetrahydro-5H-ben-
zocyclohepten-5-yl)-amino]-methyl}-benzoic acid methyl 
ester (21i) 
Yield: 54%; IR (DCM) ?max 3430, 3058, 3024, 2931, 
1721, 1683, 1435, 1279; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 
1.34-2.11 (4 x m, 10H, 5 x CH2), 2.46-2.58 (m, 1H, 1H of 
CH2CO), 2.63-2.72 (m, 1H, 1H of CH2CO), 3.31 (br. d, 1H, 
NCHCH=CH), 3.72-3.76 (m, 1H, NCHAr), 3.83-3.97 (s and 
m, signals overlapping, 4H, 3H of CH3OCO- and 1H of 
NCH2 ), 4.06-4.13 (m, 1H, 1H of NCH2), 5.62-5.76 (m, 2H, 
CH=CH), 7.25-7.29 (m, 1H, Ar-H), 7.42-7.50 (m, 4H, 4 x 
Ar-H), 7.74 and 7.80 (2 x d, 1H, J=7.52Hz, Ar-H), 7.96 and 
7.97 (2 x d, 2H, J=8.04Hz, 2 x Ar-H); 
13
C NMR (CDCl3, 
100MHz) ?ppm = 19.8 and 20.1 (CH2), 21.4 and 21.5 (CH2), 
24.5, 24.6, 24.7, 26.4 (2 x CH2), 29.1 and 29.7 (CH2), 40.1 
and 40.2 (CH2), 2 x 50.8 (CH2), 50.7 and 51.6 (CH2), 51.5 
(CH3), 55.4 and 55.5 (CH), 61.5 and 61.8 (CH), 126.7 and 
126.8 (tert. C), 126.9 and 127.1 (tert. C), 127.2, 2 x 127.3, 2 
x 127.4, 127.6 (3 x tert. C), 2 x 128.0 (2 x quat. C), 4 x 129.1 
(2 x tert. C), 129.1, 129.9, 2 x 130.3, 130.5 (CH=CH), 2 x 
130.9 (tert. C), 138.7 and 138.8 (quat. C), 141.9 and 142.8 
(quat. C), 146.9 and 147.7 (quat. C), 2 x 166.5 (COOCH3), 
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205.7 and 206.6 (C=O); HRMS (M+Na)
+
426.2053, 
C26H29NO3Na requires 426.2045. 
4-{[Cyclohex-2-enyl-(9-oxo-6,7,8,9-tetrahydro-5H-benz-
ocyclohepten-5-yl)-amino]-methyl}-phenyl)-acetic acid 
methyl ester (21j) 
Yield: 23%; IR (DCM) ?max 3400, 3058, 3019, 2928, 
1739, 1682, 1435, 1262; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 
1.28-2.22 (3 x m, 10H, 5 x CH2), 2.56-2.60 (m, 1H, 1H of 
CH2CO), 2.65-2.75 (m, 1H, 1H of CH2CO), 3.35 (br. d, 1H, 
NCHCH=CH), 3.64 (2 x overlapping s, 2H, Ar-CH2COO-), 
3.71 (s, 3H, CH3OCO-), 3.73-3.97 (m, 2H, NCH2), 4.15-4.18 
(m, 1H, NCHAr), 5.65-5.80 (m, 2H, CH=CH), 7.25 (2 x 
overlapping d, 2H, J=8.02Hz, 2 x Ar-H), 7.32 (t, 1H, 
J=7.52Hz, Ar-H), 7.39 and 7.41 (1 x d, J=8.00Hz and 1 x d 
J=9.56Hz, 2H, 2 x Ar-H), 7.48-7.63 (m, 2H, 2 x Ar-H), 7.84 
and 7.94 (2 x d, 1H, J=8.02Hz, Ar-H); 
13
C NMR (CDCl3, 
100MHz) ?ppm = 20.4 and 20.7 (CH2), 22.0 and 22.7 (CH2), 
25.1 and 25.2 (CH2), 25.4 and 26.9 (CH2), 29.6 and 30.4 
(CH2), 40.6 and 40.7 (CH2), 2 x 40.8 (CH2), 50.7 and 51.6 
(CH2), 52.1 (CH3), 55.6 and 55.8 (CH), 61.0 and 61.6 (CH), 
126.5 and 126.6 (tert. C), 2 x 127.1 (CH=CH), 2 x 127.3 
(tert. C), 2 x 127.8 (CH=CH), 4 x 128.7 (2 x tert. C), 129.9 
and 130.0 (tert. C), 130.2 and 130.3 (tert. C), 2 x 130.9 (tert. 
C), 131.6 and 131.7 (quat. C), 138.6 and 138.8 (quat. C), 
139.9 and 140.8 (quat. C), 142.7 and 143.8 (quat. C), 2 x 
171.8 (COOCH3), 205.8 and 206.8 (C=O); HRMS 
(M+Na)
+
440.2211, C27H31NO3Na requires 440.2202. 
9-(Biphenyl-2-ylmethyl-cyclohex-2-enyl-amino)-6,7,8,9-
tetrahydro-benzocyclohepten-5-one (21k) 
Yield: 41%; IR (DCM) ?max 3396, 3053, 2918, 1684, 
1451, 1038; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 1.26-1.95 (4 
x m, 10H, 5 x CH2), 2.44-2.65 (m, 2H, CH2CO), 3.22 (br. m, 
1H, NCHCH=CH), 3.62-3.69 (m, 1H, NCHAr), 3.83-3.98 
(m, 2H, NCH2), 5.48-5.73 (2H, m, CH=CH), 7.18 (d, 1H, 
J=7.32Hz, Ar-H), 7.27 (d overlapping signals, 4H, 
J=5.84Hz, 4 x Ar-H), 7.35-5.55 (m, 6H, 6 x Ar-H), 7.75 and 
7.92 (2 x d, 1H, J=7.28Hz, Ar-H), 7.82 and 7.85 (2 x d 
overlapping, 1H, J=7.32Hz, J=8.04Hz, Ar-H); 
13
C NMR 
(CDCl3, 100MHz) ?ppm = 20.3 and 20.6 (CH2), 22.0 and 22.1 
(CH2), 2 x 25.1 (CH2), 25.4 and 27.0 (CH2), 29.1 and 30.1 
(CH2), 40.6 and 40.7 (CH2), 47.7 and 48.3 (CH2), 55.2 and 
55.3 (CH), 60.6 and 60.9 (CH), 125.6 and 125.7 (tert. C), 
126.4 and 126.5 (tert. C), 2 x 127.0 (tert. C), 2 x 127.2 (tert. 
C), 127.4, 127.5, 127.6, 128.6, 128.7, 8 x 128.9, 129.4, 
129.5, 2 x 129.9, 130.1, 130.4, 130.9 (CH=CH and 9 x tert. 
C), 138.1 and 138.6 (quat. C), 138.8 and 138.9 (quat. C), 
140.0 and 140.6 (quat. C), 140.9 and 141.0 (quat. C), 142.7 
and 143.7 (quat. C), 206.0 and 206.9 (C=O); HRMS (M+H)
+
 
422.2478, C30H32NO requires 422.2484. 
9-(Benzhydryl-cyclohex-2-enyl-amino)-6,7,8,9-tetra-
hydro-benzocyclohepten-5-one (21l) 
Yield: 32%; IR (DCM) ?max 3391, 3063, 3029, 2928, 
1681, 1595, 1449, 1279; 
1
H NMR (CDCl3, 600 MHz) ?ppm = 
1.45-2.20 (5 x m, 10H, 5 x CH2), 2.22-2.50 (m, 1H, 1H of 
CH2CO), 2.54-2.66 (m, 1H, 1H of CH2CO), 3.95 and 4.03 (2 
x br. m, 1H, NCHCH=CH), 4.47-4.51 (m, 1H, 
NCH(Ar)CH2), 5.41 and 5.50 (2 x s, 1H, NCH(Ar)Ar), 5.79-
5.87 (m, 1H, CH=CH), 5.91-5.99 (m, 1H, CH=CH), 7.14-
7.42 (m, 9H, 9 x Ar-H), 7.53 (t, 1H, J=7.70Hz, Ar-H), 7.57 
(m, 1H, Ar-H), 7.63 (t, 1H, J=7.40Hz, Ar-H), 7.78, 7.84, 
7.95 (3 x overlapping d, 2H, J=7.92Hz, J=7.14Hz, 2 x Ar-
H); 
13
C NMR (CDCl3, 150Hz) ?ppm = 20.1 and 20.3 (CH2), 
22.5 and 22.8 (CH2), 25.0 and 25.1 (CH2), 30.3 and 30.7 
(CH2), 32.1 and 32.2 (CH2), 40.4 and 40.6 (CH2), 55.5 and 
55.7 (CH), 58.7 and 59.0 (CH), 65.7 and 65.9 (CH), 125.9, 2 
x 126.3, 126.5, 126.7, 126.8, 127.0, 127.3, 127.4, 127.5, 
127.7, 127.8, 127.9, 128.0, 2 x 128.1, 3 x 128.2, 128.3, 
128.6, 128.9, 129.4, 130.1, 130.3, 130.4, 131.1, 131.4, 131.7, 
132.4, 2 x 133.0 (CH=CH and 14 x tert. C), 138.1, 138.3, 
143.5, 143.6, 144.0, 144.8, 144.9, 145.2 (4 x quat. C), 206.3 
and 206.7 (C=O); HRMS (M+Na)
+
 444.2318, C30H31NONa 
requires 444.32303. 
9-[Cyclohex-2-enyl-(4-nitro-benzyl)-amino]-6,7,8,9-tet-
rahydro-benzocyclohepten-5-one (21m) 
Yield: 64%; IR (DCM) ?max 3406, 3063, 3015, 2929, 
1683, 1599, 1518, 1344; 
1
H NMR (CDCl3, 400 MHz) ?ppm = 
1.37-2.11 (2 x m, 10H, 5 x CH2), 2.55-2.67 (m, 1H, 1H of 
CH2CO), 2.68-2.71 (m, 1H, 1H of CH2CO), 3.37-3.45 (br. 
m, 1H, NCHCH=CH), 3.81-3.97 (m, 2H, NCH2), 4.14-4.17 
(m, 1H, NCHAr), 5.64-5.82 (m, 2H, CH=CH), 7.25-7.31 (m, 
1H, Ar-H), 7.41-7.50 (m, 3H, 3 x Ar-H), 7.53 (d, 1H, 
J=8.8Hz, Ar-H), 7.70 (d, 1H, J=7.76Hz, Ar-H), 8.08-8.15 
(m, 2H, 2 x Ar-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 20.2 
and 20.4 (CH2), 2 x 21.9 (CH2), 2 x 25.1 (CH2), 25.2 and 
26.3 (CH2), 29.6 and 30.0 (CH2), 40.7 and 40.9 (CH2), 51.5 
and 51.9 (CH2), 2 x 56.1 (CH), 62.7 and 62.9 (CH), 2 x 
123.4 (tert. C), 2 x 123.5 (tert. C), 127.4 and 127.7 (tert. C), 
2 x 127.5 (tert. C), 127.9 and 128.2 (tert. C), 2 x 128.3 (tert. 
C), 2 x 128.5 (tert. C), 129.3, 129.7, 130.5, 131.2 (CH=CH) 
2 x 131.4 (tert. C), 139.2 and 139.5 (quat. C), 141.9 and 
142.5 (quat. C), 146.6 and 146.7 (quat. C), 149.9 and 150.7 
(quat. C), 206.4 and 207.1 (C=O); HRMS (M+H)
+
 391.2013, 
C24H27N2O3 requires 391.2314. 
4-{[Cyclohex-2-enyl-(9-oxo-6,7,8,9-tetrahydro-5H-ben-
zocyclohepten-5-yl)-amino]-methyl}-benzonitrile (21n) 
Yield: 85%; IR (DCM) ?max 3428, 3067, 3024, 2929, 
2226, 1683, 1606, 1449, 1100; 
1
H NMR (CDCl3, 400 MHz) 
?ppm = 1.37-2.11 (3 x m, 10H, 5 x CH2), 2.50-2.60 (m, 1H, 
1H of CH2CO), 2.65-2.75 (m, 1H, 1H of CH2CO), 3.39 (br. 
m, 1H, NCHCH=CH), 3.75-3.93 (m, 2H, NCH2), 4.11-4.14 
(m, 1H, NCHAr), 5.62-5.80 (m, 2H, CH=CH), 7.28 (2 x 
overlapping t, 1H, J=8.00Hz, Ar-H), 7.39-7.49 (m, 4H, 4 x 
Ar-H), 7.54 and 7.58 (1 x d, J=8.04Hz and 1 x d, J=8.52Hz, 
2H, 2 x Ar-H), 7.68 and 7.70 (2 x overlapping d, 1H, 
J=3.52Hz, COAr-H); 
13
C NMR (CDCl3, 100MHz) ?ppm = 
19.8 and 20.0 (CH2), 21.4 and 21.5 (CH2), 24.7 x 3, 25.9 (2 x 
CH2), 29.1 and 29.5 (CH2), 40.2 and 40.4 (CH2), 51.2 and 
51.6 (CH2), 2 x 55.6 (CH), 62.2 and 62.3 (CH), 109.5 and 
109.6 (quat. C), 118.7 (CN), 126.9, 2 x 127.0, 127.2, 127.3, 
127.7 (3 x tert. C), 2 x 127.9 (tert. C), 2 x 128.0 (tert. C), 
128.9, 129.3, 130.7, 130.8 (CH=CH), 130.9, 131.0 (tert. C), 
2 x 131.5 (tert. C), 2 x 131.6 (tert. C), 138.7 and 139.0 (quat. 
C), 141.5 and 142.1 (quat. C), 147.2 and 148.0 (quat. C), 
205.9 and 206.7 (C=O); HRMS (M+Na)
+
 393.1926, 
C25H26N2ONa requires 393.1943. 
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CONCLUSION 
This paper presents the results of an assessment of the 
potential anti-allergic applications of a novel series of 
cyclohexenylamino derivatives of tetralone and 
benzosuberone. In vitro investigation of the mast cell-
stabilising activity revealed that within series 20 and 21, 
optimal activity appeared to reside in a tertiary amine 
bearing either parent bicyclic system, an unsaturated 
cyclohexene, and thirdly, a benzyl or substituted benzyl 
motif. It further appears that for in vivo activity the 
unsaturated alicyclic system on nitrogen is critical, both from 
results observed with 20e and derivatives of 21. This 
suggests that while ring expansion of the hydroaromatic core 
is permissible without loss of activity in vivo, there must be 
an unsaturated alicyclic component. We intend to expand on 
this premise in future studies. 
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